Semaglutide and Tirzepatide: A Dietitian's 2026 Clinical Guide

What every clinician should know about GLP-1 and dual GIP/GLP-1 receptor agonists for weight management

What is the dietitian’s role in GLP-1 therapy?

Registered dietitians are central to safe and effective GLP-1 receptor agonist therapy. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) produce 14-23% mean total body weight loss at 72 weeks in adults with obesity, but they also reduce protein intake, micronutrient density, and lean mass in a substantial subset of patients. Dietitians manage the nutritional sequelae these drugs predictably create.

This guide covers the 2026 evidence base — pharmacology, appetite mechanisms, GI side-effect mitigation, lean mass preservation, and discontinuation planning — at the level a practicing RDN needs in clinic.

Why this matters: Without structured nutrition support, ~25-39% of weight lost on GLP-1 therapy is lean mass (Zhang et al., 2024). That figure is comparable to dietary weight loss alone, but the absolute loss is larger because total weight loss is larger. Sarcopenic obesity, falls, and metabolic adaptation are real risks at the population level — and they are largely modifiable by an RD-led care plan.

How do GLP-1 and GIP receptor agonists work?

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient intake. It slows gastric emptying, suppresses glucagon, augments insulin secretion in a glucose-dependent manner, and acts centrally in the hypothalamus and brainstem to reduce hunger and food reward.

Semaglutide is a synthetic GLP-1 analog with a half-life of ~7 days, dosed once weekly subcutaneously. Tirzepatide is a “twincretin” — a single peptide that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual mechanism is thought to explain its larger weight-loss effect, although head-to-head trials at matched doses are limited.

Trial benchmarks clinicians should know

What are the most common GI side effects, and how do RDs mitigate them?

Nausea, constipation, and reflux dominate the side-effect profile. In STEP 1, 74.2% of semaglutide patients reported any GI event vs 47.9% on placebo, with most events mild-to-moderate and concentrated in the titration phase (Wharton et al., 2022).

Practical mitigation strategies that work in clinic:

• Smaller, more frequent meals. A typical “three squares” eating pattern often becomes intolerable. Patients usually do better with 4-5 small structured meals.
• Reduce fat density during titration. High-fat, fried, or very rich meals predictably trigger nausea because gastric emptying is already slowed.
• Front-load protein at breakfast. Appetite is typically highest in the morning; protein intake at the end of the day is most likely to be missed.
• Treat constipation proactively. Adequate hydration, 25-35 g/day fiber where tolerated, and low-osmolar laxatives like polyethylene glycol when needed.
• Plan around dose-escalation weeks. Most GI burden clusters in the 2-4 days after a dose increase. Defer travel and high-stakes social meals when possible.

For more detail on the food aversions and taste changes patients report, see our companion article on GLP-1 side effects and food aversions.

How much weight loss should clinicians expect — and over what timeline?

Mean weight loss at 12 weeks is typically 5-7% of baseline body weight; at 26 weeks, 10-12%; at 52-72 weeks, 14-23% depending on agent. Patients should be counseled that the loss curve is not linear: the steepest decline occurs in months 2-6, with progressive deceleration toward a plateau.

Approximately 10-15% of patients are “non-responders” — defined in trials as less than 5% weight loss at 12 weeks. Non-response is more common in patients with longer-duration obesity, type 2 diabetes, and certain genetic variants under investigation. Switching agents (e.g., semaglutide → tirzepatide) is increasingly common when initial response is inadequate.

What is the lean mass risk, and how should it be managed?

Approximately 25-39% of total weight lost on GLP-1 therapy is fat-free mass. This is not dramatically different from lifestyle-only weight loss in absolute proportion, but the larger total weight loss means absolute lean mass loss is meaningful: a 100 kg patient losing 22% body weight may lose 6-8 kg of lean tissue without intervention.

The core RD interventions are:

1. Protein target of 1.2-1.6 g/kg ideal body weight per day, distributed across 3-4 meals at 25-40 g per meal.
2. Resistance training at least 2x weekly with progressive overload across major movement patterns.
3. Adequate energy intake — under-eating below ~1,200 kcal/day for women and ~1,500 kcal/day for men will accelerate lean loss regardless of protein intake.
4. DXA or BIA at baseline and every 6 months when feasible to monitor body composition rather than total weight alone.

Detailed protocols are covered in our deeper-dive piece on preventing lean mass loss on GLP-1 therapy.

Do GLP-1 medications affect micronutrient status?

Reduced caloric intake plus altered taste and food aversions create a real risk of inadequate intake of iron, calcium, vitamin D, vitamin B12, folate, and magnesium. There is no FDA-mandated supplementation protocol, but the Academy of Nutrition and Dietetics (2024) recommends:

• Multivitamin with iron unless contraindicated
• Calcium 1,000-1,200 mg/day from diet plus supplement combined
• Vitamin D 1,000-2,000 IU/day with serum 25(OH)D check at 6 and 12 months
• B12 monitoring annually if patient also takes metformin

Patients on GLP-1s for type 2 diabetes who also take metformin are particularly vulnerable to B12 deficiency.

What about discontinuation and weight maintenance?

The discontinuation literature is sobering. STEP 4 (semaglutide withdrawal at week 20) and SURMOUNT-4 (tirzepatide withdrawal at week 36) both show that ~two-thirds of lost weight is regained within one year of stopping the drug. Hunger hormones (ghrelin), gastric emptying, and the central reward response largely return to pre-treatment patterns within weeks of discontinuation.

This finding has reframed obesity pharmacotherapy as a chronic-disease management model — analogous to antihypertensives — rather than a finite “weight loss program.” For patients who choose to off-ramp, structured tapering with intensified behavioral support is the current best practice; see off-ramping GLP-1 medications for a clinical protocol.

Are GLP-1s safe in patients with disordered eating history?

This is a clinical judgment call requiring multidisciplinary care. Active anorexia nervosa, bulimia nervosa, or binge eating disorder is generally a contraindication, though emerging data suggest possible benefit in BED specifically. A history of disordered eating is not an absolute contraindication, but warrants:

• Pre-prescribing assessment by a clinician trained in eating disorders
• Concurrent care from an RD with ED experience
• Active monitoring for restriction, food rules, and body-image deterioration during the rapid weight loss phase
• A shared decision-making conversation about the irreversibility of the choice once GI side effects begin

The Academy of Nutrition and Dietetics 2024 position paper explicitly names dietitians as the appropriate clinician to lead this assessment.

What about cardiovascular and renal outcomes?

The evidence base now extends well beyond weight loss. SELECT (semaglutide, 2023) showed a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and obesity without diabetes. FLOW (semaglutide, 2024) showed renal benefit in CKD with type 2 diabetes. SUMMIT (tirzepatide, 2024) showed clinical improvement in heart failure with preserved ejection fraction and obesity. These outcomes are reshaping prescribing guidelines for indications beyond weight management alone.

What should the first GLP-1 nutrition visit cover?

A typical 60-minute initial RD visit for a GLP-1 patient should include:

What tools help patients track intake during titration?

Tracking is useful but contextual. During titration, when intake is genuinely reduced, simple protein-and-fluid logs often outperform full calorie tracking — they keep attention on adequacy rather than restriction. Patients with a history of disordered eating should not be asked to track without supervision. For those who do benefit from a structured digital log, the choice of tool matters less than the clinician’s review of the data; you can see our evaluation of consumer nutrition apps for a comparative view.

Bottom line for clinicians

GLP-1 and dual GIP/GLP-1 receptor agonists are now a standard-of-care option for obesity. They are not a substitute for nutritional care — they are a context in which structured, RD-led nutritional care becomes more important, not less. The 2026 frontier is no longer whether they work, but how to optimize composition of weight loss, manage off-ramping, and screen for vulnerable subgroups including those with sarcopenic obesity (covered in our companion piece on sarcopenic obesity screening on GLP-1s) and patients with disordered eating histories.

The right glossary entry on lean mass and GLP-1 receptor agonist definition are useful starting points for newer trainees.